Upload
felicia-fields
View
226
Download
0
Embed Size (px)
Citation preview
How to performed dialysis circuit with ECMO
蔡壁如2011-8-25
1996-2010 ECMO + Dialysis data
Survival rate
MCS (307/73) 23.8%
Septic shock (14/3) 21.4%
ARDS (72/22) 30.5%
LTx (7/0) 0.00%
24.5%
ECMO Data base : 900 / 400 ( 44.4% )
Outline
• Case presentation
• Critical dialysis in ECMO patients
• Data report
Case Presentation
• 林 x x Chart NO:4462271
• NTUH Admission date:2011-5-14– SICU Admission date:2011-5-14– Severe septic shock with ARDS
• Expired date:2011-6-13– Total SICU stay :30 days
Patient history
• This 44 yrs man had no systemic disease before.
• Suffered general malaise and joint pain (3 月 ) 中山醫學院附設醫院: with bilateral dorsal
hands swelling, local heat and pain were found. visited 中國 hospital where lab data showed
rheumatic factor 400. • Rheumatoid arthritis was diagnosed.
Patient Course
• Symmetric polyarthitis of hands was found. • Body weight loss 6kg in one month. • Under the impression of acute RA, he was
admitted and systemic steroid and Mabthera infusion.
• MTX (Methotrexate 4# Q7D) was also added. • The symptoms of RA improved after
treatment. Discharge
Patient Course
• 4/28 ER– Shortness of breath, dry cough were noted.– CXR showed diffuse bilateral alveolar
infiltration.– Hypoxia was noted.– Chest CT showed diffuse peribronchial
parenchyma and alveolar inflammatory change.
– Acute lung injury was impressed. • 4/30 Admitted to MICU
Patient Course• BiPAP and relative clear bilateral breathing sound
and scanty sputum was noted. • Tazocin was given (2011/04/30~2011/05/04). • Tamiflu 75mg for 5 days (2011/04/30~2011/05/04). • Hydrocortisone 100mg Q8H for RA and ARDS.• 5/4
– Intubated SpO2 90%, FiO2: 0.9, PEEP15,TV 600ml.– Gancyclovir 500mg Q12h for possible CMV infection.
• 5/5 – IVIG. – Antibiotics were then shifted to Vancomycin and Tienam. – Diflucan.
Patient Course• 5/10
– MTX related interstitial pneumonitis was suspected.
– CDC reported CMV RT-PCR positive
• 5/11– Cytotect 2ml/kg – On ECMO due to severe ARDS
• OI: 41.6, AaDO2:610• FiO2:1.0, PaO2 :48
• 5/13– Sputum culture showed MDRAB– Tygacil was added
Treatment Course5-14 Transferred to NTUH V-V ECMO5-14 Tienam,Tygacil, Colistin,
Sevatrimsputum culture MDRAB and possible PCP
5-14 Xigris for severe sepsis
U/O : 125 cc/8hrSolu-cortef 100mg q6h
c-SLEDD-f on ECMODialysate:100cc/min, UF rate:35cc/kg/hr
Blood flow:300cc/min
HCO2:26, K:4
net UF : as titration
5-15 SpO2 : 85%, Pneumothorax over left lower
V-VA①RFV RIJV VV-ECMO②RFV Left axillary V-A ECMO
Tygacil 5/13 ~
Tienam 5/14 ~ 5/15, Cravit 5/17 ~
Sevatrim 5/14 ~
Clinmycin 5/14 ~
2011-5-14
SLEDD-f on ECMO
Early goal-directed hemofiltration therapy
• Pulse high volume therapy : 96hr– 1. 100 cc/Kg/hr X 4hr, then 50cc/Kg/hr X 92hr– 2. Simultaneous APC (Xigirs) therapy – 1+2 keep 96hr
• 5/18 CAVH on ECMO : 2000 cc//hr
Treatment Course• 5/18
– Xigris finish : SLEDD-f shift to CAVH
– IVIG given : hypogammaglobulinemia 5/18 ~ 5/22• C3 : 53.2 、 C4 : 13.9• IgA : 94.1 、 IgG : 630 、 IgM : 24.3• RA Factor (Nephelometry)(IU/mL) : 32.30
• 5/24– Septic shock
• CVP : Acinetobacter baumannii (MDRAB)3+
• CVP : Enterobacter cloacae• bronchial washing : Acinetobacter baumannii(MDRAB)3+
– CAVH shift to 5008HF (70cc/kg/hr)
Treatment Course• 6/5
– V-A ECMO A-cannula clot : removal and re-on
• 6/9– X-ray : Bilateral hemothorax and empyema– CT : large hyperdense hematoma (18.4cm) in left
subphrenic area and basal lung.
• 6/10 OP – VATS exploration and decortication, bilateral– The blood loss is about 1300(L) + 700(R)ml– Tracheostomy
• 2011/06/11~06/13– Bleeding tendency and profound shock– Expired
60
65
70
75
80
85
90
95
514
月日
515
月日
516
月日
517
月日
518
月日
519
月日
520
月日
521
月日
522
月日
523
月日
524
月日
525
月日
526
月日
527
月日
528
月日
529
月日
530
月日
61
月日
62
月日
63
月日
64
月日
65
月日
66
月日
67
月日
68
月日
69
月日
610
月日
611
月日
612
月日
613
月日 0
50
100
150
200
250
300BW
U/O
Xigirs CAVH (35cc/kg/hr)
c-SLEDD-f 5008 HF (70cc/kg/hr)
IVIG
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
514
月日
515
月日
516
月日
517
月日
518
月日
519
月日
520
月日
521
月日
522
月日
523
月日
524
月日
525
月日
526
月日
527
月日
528
月日
529
月日
530
月日
61
月日
62
月日
63
月日
64
月日
65
月日
66
月日
67
月日
68
月日
69
月日
610
月日
611
月日
612
月日
613
月日
0
5
10
15
20
25
30
35
40
WBC
CRP
Xigirs : 5/14 ~ 5/17
Tygacil
Colistin IVF+IH
Sevatrim
Cravit Diflucan
Sputum 5/14 ~ 6/12 : Acinetobacter baumannii(MDRAB) 1+ ~ 3+Blood culture : 5/22 Acinetobacter baumannii(MDRAB)1+ ~ 3+Sputum & wound : 6/9 Pseudomonas aeruginosa 3+CVP culture 5/26 : Enterobacter cloacae
ARDS data
0
50
100
150
200
250
300
350
400
0
10
20
30
40
50
60
70TV
MAP
PaO2
5/15 Left Pneumothorax
5/25 Right Pneumothorax
6/9Bilateral hemothorax and empyema
Nutrition
60
65
70
75
80
85
90
95
514
月日
515
月日
516
月日
517
月日
518
月日
519
月日
520
月日
521
月日
522
月日
523
月日
524
月日
525
月日
526
月日
527
月日
528
月日
529
月日
530
月日
61
月日
62
月日
63
月日
64
月日
65
月日
66
月日
67
月日
68
月日
69
月日
610
月日
611
月日
612
月日
613
月日 0
50
100
150
200
250
300BW
U/O
Cal : 120014402160 2400 2880
Protein: 1g/Kg 1.5g/Kg2.0g/Kg
Alb:5/14(3.3) 5/20(2.8) 5/29(2.2) 6/12 (2.2)
P : 5/16(1.0) 5/19(2.6) 5/23(2.8) 5/25(2.0) 6/2(2.4) 6/6(1.4) 6/9(2.1) 6/12(2.8)
Critical dialysis in ECMO patient
• CAVH on ECMO
• 5008 c-SLEDD-f on ECMO
• 5008 HF on ECMO
Continuous dialysis by gravity through the filter of extracorporeal membrane oxygenation
Nephrol Dial Transplant. 2007 Dec;22(12) : 3676-7.
血流方向:動脈導管側孔到靜脈導管(PG:120~150 mmHg)
CAVH flow by Transonic HT100 transducer measure and by screw control: 300~400cc/min
UF rate: 2000 cc/hrReplacement fluid: Sintom A + B solution Net UF rate: as titration
血流方向:氧合器側孔到靜脈導管(PG:120~150 mmHg)
CAVH flow by Transonic HT100 transducer measure and by screw control: 300~400cc/min
UF rate: 2000 cc/hrReplacement fluid: Sintom A + B solution Net UF rate: as titration
血流方向:氧合器側孔到動脈導管(PG: mmHg)
Blood flow : 300 cc/minDialysate: 100 ~ 800 cc/minHCO3: 26 ~ 32K+: 2 ~ 4Replacement fluid:35 cc/kg/hrDuration : Method : c-SLEDD-f, HF(CVVH)
Guideline
• CAVH :不需額外機器驅動,不佔空間– Standard UF 35 cc/kg/hr– BW ≒ ↓60Kg – Sintom A + B solution 缺 K+
• 5008 HF :全自動,第一線護理師滿意度高– High volume UF – Early goal-directed hemofiltration therapy– Big BMI ↑60Kg –大系統 +RO機
Early goal-directed hemofiltration therapy
Early goal-directed hemofiltration therapy
• Pulse high volume therapy : 96hr– 1. 100 cc/Kg/hr X 4hr, then 50cc/Kg/hr X 92hr– 2. Simultaneous APC (Xigirs) therapy – 1+2 keep 96hr, then 35cc/Kg/hr
HF-400 or Prismaflex
•可不可以接 ECMO X • 驅動感應器不同 : artery sensor一定要負壓• 引流管線接在負壓區 (V-cannula) ?
– 小系統≠大系統負值太小 Alarm
•獨立系統: Double lumen–選項問題
ECMO + Dialysis data report
• Inclusion criteria – 1996-2010 ECMO + Dialysis– ≥ 16yrs – ≥ 3 days ICU stay
• Exclusion criteria – ≤15 yrs– ECMO + Dialysis 48hrs≦
1996-2010 ECMO + Dialysis data
Survival rate
MCS (307/73) 23.8%
Septic shock (14/3) 21.4%
ARDS (72/22) 30.6%
LTx ( 7/0) 0.00%
24.5%
ECMO Data base : 900 / 400 ( 44.4% )
Two stage data
Survival rate
1996-2005
(16.2%)
2006-2010
(31.2%)
MCS 142/23 (16.1%) 165/50 (30.3%)
Septic shock 4/0 (0%) 10/3 (30%)
ARDS 26/6 (23.0%) 46/16 (34.7%)
LTx 7/0 (0%)
兩個時期不同處• CAVH• CVVH• IHD
• CAVH• CVVH• SLEDD• SLEDD-f• C-SLEDD-f• Plasmaphresis
Data
• 1996-2005 data
• 2006-2010 data
• 1996-2010 data